MRNS DEADLINE: TOP RANKED ROSEN LAW FIRM Encourages Marinus Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 5 Deadline in Securities Class Action First Filed by the Firm – MRNS

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Marinus Pharmaceuticals, Inc. securities between March 17, 2021, and May 7, 2024, of the August 5, 2024, deadline to serve as lead plaintiff in a securities class action lawsuit [1][2]. Group 1: Case Details - The lawsuit alleges that during the Class Period, defendants made materially false and misleading statements regarding the risks associated with the RAISE trial, including the failure to meet early-stopping criteria, which could lead to the cessation of the Phase 3 RAISE II trial [3]. - The lawsuit claims that when the true details were revealed, investors suffered damages due to the misleading nature of the defendants' statements about the company's business and prospects [3]. Group 2: Class Action Participation - Investors who purchased Marinus securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [5]. - Until a class is certified, investors are not represented by counsel unless they retain one, and they can choose to remain absent from the class [4].